As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
The STATUS Trial
The purpose of this study is to evaluate the efficacy and safety of an investigational medicine compared to placebo for the treatment of super-refractory status epilepticus. This is a multicenter trial seeking to recruit 140 patients. The treatment will be assigned randomly.
In order to participate you must meet the following criteria:
- Have failed to respond to the administration of at least one first-line agent (e.g., benzodiazepine or other emergent initial AED treatment).
- Have failed to respond to at least one second-line agent (e.g., phenytoin, fosphenytoin, valproate, phenobarbital, levetiracetam or other urgent control AED.
You will be excluded from the study if any of the following criteria apply to you:
- Have certain medical conditions.
This is a partial list of inclusion and exclusion criteria.